From sourcing raw APIs to final packaging — every decision at Amro Pharmaceuticals is guided by a single principle: quality that a doctor can trust and a patient can rely on.
Quality is not a department at Amro — it is the operating culture. From the first API inquiry to the final dispatch, every step is governed by clear, non-negotiable standards.
We do not add products to our portfolio reactively. Each new formulation undergoes a formal selection committee review — evaluating clinical relevance, market demand, margin feasibility, and patient safety profile before acceptance.
Every manufacturing partner in our network must hold valid GMP, WHO-GMP, or ISO 9001 certification. We conduct periodic audits and review batch analysis reports before approving any vendor relationship.
Active pharmaceutical ingredients are sourced only from registered, CDSCO-approved API manufacturers. We maintain complete traceability from raw material to finished product to ensure the integrity of every batch.
Feedback from our franchise network, stockists, and medical community is systematically tracked. Any quality concern triggers a structured review and corrective action — never shelved, always resolved.
While our manufacturing is partner-based, we hold our vendors to standards as demanding as in-house production — because the patient does not differentiate.
Amro follows an asset-light model — we work with approved CMO (Contract Manufacturing Organization) partners across India. This model enables agility, scale, and specialization without compromising the quality mandate.
Our vendor agreements include mandatory provisions for:
Over 90% of our core formulations — tablets, syrups, and drops — are manufactured in strict adherence to Indian Pharmacopoeia specifications regulated by the IPC.
Advanced therapeutic molecules (e.g., Nimesulide in Senna-MD) strictly align with BP dissolution assays and molecular purity specifications.
Nutritional, mineral, and fatty acid softgels (e.g., Calbon, Toconeu) are produced using USP-approved source materials and testing specifications.
The right product in the right market makes all the difference. Our product strategy is rooted in ground-level intelligence, clinical feedback loops, and data-driven selection.
Our product development process begins long before manufacturing. The Amro team actively engages with physicians, pharmacists, and franchise partners across India to identify therapeutic gaps and underserved patient segments.
This ground intelligence is combined with national prescription audit trends to build a portfolio that is both clinically relevant and commercially viable.
Every product in the Amro portfolio has passed through this structured review process.
Field team identifies therapeutic gap or underserved molecule
Molecule reviewed for safety profile, Rx status, and pharmacopoeia compliance
Manufacturer shortlisted based on GMP certifications and batch history
Pricing modelled to ensure affordability for patients and viability for stockists
Product launched with visual aid, monitoring of feedback and reorders
Quality control at Amro is a continuous process — not a one-time checkpoint. It operates at every interface between vendor, product, and patient.
Every consignment received from a manufacturing partner must be accompanied by a valid Certificate of Analysis (CoA). We cross-verify key parameters — potency, dissolution, moisture content, and microbial limits — before acceptance into inventory.
Our team conducts physical inspection of packaging at the time of receipt — checking sealing integrity, strip quality, label accuracy, and expiry marking. Products failing visual standards are quarantined and returned.
Our warehouse maintains temperature and humidity logs for sensitive products. Cold-chain products are handled under special provisions with documented temperature records throughout the supply chain.
We maintain a documented complaint register and batch-level traceability for all products. In the event of a quality concern, the Grievance Desk initiates a structured recall or replacement procedure within 48 hours.
Trust is the most durable asset in pharmaceuticals. Every policy at Amro is designed to protect that trust — with doctors, with patients, and with our distribution partners.
All products are manufactured, labelled, and distributed in compliance with the Drugs and Cosmetics Act, 1940, and the Rules framed thereunder.
Prescription-only formulations in our portfolio are strictly handled under Schedule H protocols — never promoted for OTC sale and always dispensed on valid Rx.
An open Grievance Desk — overseen by Aryan Khanna and the Director's office — ensures all quality or service concerns from distributors, doctors, or patients receive prompt documented resolution.
Have a quality question or vendor partnership inquiry?